Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Golimumab: Phase III data

Golimumab met the primary endpoint of ACR 20 response at week 14 in the placebo-controlled Phase III GO-REVEAL trial in 405 psoriatic

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE